The Control of Gene Expression Laboratory has recently started at QIMR Berghofer, focusing on the control of gene expression. The leader of the laboratory, Frank Gannon, has been active in this area of research for very many years, but had interrupted his research career when he took a position as Director General of Science Foundation Ireland, the national funding agency in Ireland. He moved to Brisbane as the Director and CEO of QIMR Berghofer in 2011 and now has established a research activity there.
The research of the group is designed to achieve a better understanding of the specifics of the control of gene expression. The most recent research on which the current projects are built was the demonstration of transient cyclical DNA methylation and demethylation (Kangaspeska et al., Nature 452, 2008). This work followed from earlier detailed analysis of the processes by which the estrogen receptor recruited the RNA polymerase and initiated transcription (Métivier et al., Cell 115, 2003; Métivier et al., EMBO reports 7, 2006).
A focus on histone modifications that occur in conjunction with the onset and silencing of transcription has been the focus of the work of Dr Jason Lee who has joined the laboratory. His research activities grow from the histone modification aspects through to the effects of modifying enzymes on other cellular targets and their consequences in cellular physiology.
Whereas the focus of the group radiates from the estrogen receptor, the general questions of epigenetic control of gene expression will be examined in diverse systems. In all cases the aim is to develop insights that can be translated to different disease settings.
Group Leader: Professor Frank Gannon
- Associate Professor Jason Lee, QIMR Berghofer International Research Fellow
- Dr Eva Baxter, Research Officer
- Karolina Windloch, Research Assistant
The Control of Gene Expression Laboratory is designed to achieve a better understanding of the specifics of the control of gene expression. The group concentrates on integrating chromatin and DNA epigenetic changes in various cancer types.
- Combining epigenetic drugs with immunotherapy in melanoma
- Determining the therapeutic efficacy of epigenetic drugs in ovarian cancer
- Identification of new epigenetic modification targets in breast cancer
If you wish to apply for QIMR Berghofer's student program,
click here for more information.